Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, has secured $5.7 million in financing to support the clinical development of Rhenium (186Re) Obisbemeda for leptomeningeal metastases (LM), as well as further development of the company’s CNSide LM diagnostic test as a pivotal trial endpoint. The funding includes approximately $3.7 million from a private placement and a $2.0 million advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT).
Company Information
Company
Plus Therapeutics
Location
4200 MARATHON BLVD.
Austin, Texas, United States
About
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs, including Austin and San Antonio, Texas.
AustinManufacturingBiotechnologyHealth CarePharmaceutical